SynthesisFrontiers in immunology2022
The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review.Medical oncology (Northwood, London, England) · 2026Review
- Article
- Exploration of the roles of SSR2 in hepatocellular carcinogenesis based on single-cell transcriptomics and spatial transcriptomics.Discover oncology · 2026Article
- Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation.Journal of clinical medicine · 2026Article
- Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).JHEP reports : innovation in hepatology · 2026Article
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.Nature cancer · 2025Article
- Dissecting the heterogeneity and tumor-associated dynamics of human liver group I ILC via scRNA sequencing data.Immunologic research · 2025Article
- Article
- Association of Immune Cell Subsets With Longevity: The Cardiovascular Health Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Beyond Adaptive Immunity: Trained Innate Immune Responses as a Novel Frontier in Hepatocellular Carcinoma Therapy.Cancers · 2025Review
- Article
- A 41-marker 37-color full spectrum flow cytometry panel for the deep immunophenotyping of human peripheral and liver natural killer cells.Frontiers in immunology · 2025Article
- Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.Clinical and experimental medicine · 2023Article
- Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.Hepatology international · 2023Article
- Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses.Pharmaceutics · 2023Article
- Prognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Natural killer (NK) cells play major roles in eliminating tumor cells. Preliminary studies have shown that NK cells and their receptors/ligands have prognostic value in malignant tumors. However, the relevance of NK cells and their receptors/ligands level to the prognosis of hepatocellular carcinoma (HCC) remains unclear. Methods: Several electronic databases were searched from database inception to November 8, 2021. Random effects were introduced to this meta-analysis. The relevance of NK cells and their receptors/ligands level to the prognosis of HCC was evaluated using hazard ratios (HRs) with 95% confidence interval (95%CI). Results: 26 studies were included in the analysis. The pooled results showed that high NK cells levels were associated with better overall survival (HR=0.70, 95%CI 0.57-0.86, P=0.001) and disease-free survival (HR=0.61, 95%CI 0.40-0.93, P=0.022) of HCC patients. In subgroup analysis for overall survival, CD57 Conclusion: NK cells and their inhibitory receptors have prognostic value for HCC. The prognostic role of NK cell activating receptors is unclear and more high-quality prospective studies are essential to evaluate the prognostic value of NK cells and their receptors/ligands for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.